Patients in the pharmacist-led clinics were statistically more likely to be prescribed ACEI (or ARB) and beta-blocker compared with patients in the combined baseline audits (n=856/885 (97%) vs n=233/255 (91%), p<0.001 and n=813/885 (92%) vs n=224/255 (88%), p=0.048, respectively). Patient’s in the pharmacist-led clinics were also more likely to be on full target dose ACEI (or ARB) and beta-blocker compared with baseline (n=585/885 (66%) vs n=64/255 (25%), p<0.001 and n=218/885 (25%) vs n=17/255 (7%), p<0.001, respectively). The mean dose of ACEI (or ARB) and beta-blocker was also higher compared with baseline (79% vs 48% of target dose, p<0.001% and 48% vs 33% of target dose, p<0.001, respectively).